DK2767546T3 - Lipoproteinkomplekser og fremstilling og anvendelser af disse - Google Patents
Lipoproteinkomplekser og fremstilling og anvendelser af disse Download PDFInfo
- Publication number
- DK2767546T3 DK2767546T3 DK14150349.0T DK14150349T DK2767546T3 DK 2767546 T3 DK2767546 T3 DK 2767546T3 DK 14150349 T DK14150349 T DK 14150349T DK 2767546 T3 DK2767546 T3 DK 2767546T3
- Authority
- DK
- Denmark
- Prior art keywords
- cells
- culture
- embryonic stem
- stem cells
- medium
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
- C07K1/042—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers characterised by the nature of the carrier
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Toxicology (AREA)
- Marine Sciences & Fisheries (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Claims (14)
1. Fremgangsmåde til ekspansion og opretholdelse af humane embryonale stamceller (hESC'er) i en udifferentieret tilstand, hvilken fremgangsmåde omfatter dyrkning af de humane embryonale stamceller i mindst 5 passager i en suspensionskultur under dyrkningsbetingelser uden adhærens til et eksternt substrat, og som tillader ekspansion af mindst 50 % af de humane embryonale stamceller i den udifferentierede tilstand, hvor det eksterne substrat omfatter komponenter af ekstracellulær matrix, en glasmikrobærer eller glasperler, og hvor dyrkningsbetingelserne omfatter et defineret, xenofrit og serumfrit dyrkningsmedium, der er valgt fra gruppen bestående af: et dyrkningsmedium, som omfatter basisk fibroblastvækstfaktor (bFGF), en opløselig interleukin-6-receptor (slL6R) i en koncentration på mindst 10 nanogram pr. milliliter (ng/ml) og opløseligt interleukin-6 (IL6), et dyrkningsmedium, som omfatter bFGF og mindst 1000 enheder pr. milliliter (u/ml) leukæmiinhibitorfaktor (LIF), et dyrkningsmedium, som omfatter bFGF og en IL6RIL6-kimære, og et dyrkningsmedium, der omfatter bFGF og en TGFp-isoform, og hvor dyrkningsbetingelserne omfatter dyrkning af de humane embryonale stamceller i en dyrkningsbeholder med en indvendig flade, som er udformet således, at de hESC'er, der dyrkes deri, ikke kan adhærere eller binde til fladen, hvorved de humane embryonale stamceller ekspanderes og holdes i den udifferentierede tilstand.
2. Fremgangsmåde til generering af cellelinjespecifikke celler ud fra humane embryonale stamceller, hvilken fremgangsmåde omfatter, at: (a) de humane embryonale stamceller dyrkes i en suspensionskultur ifølge fremgangsmåden ifølge krav 1, hvorved der opnås ekspanderede, udifferentierede humane embryonale stamceller; og (b) de ekspanderede, udifferentierede humane embryonale stamceller underkastes dyrkningsbetingelser, der er egnet til differentiering og/eller ekspansion af cellelinjespecifikke celler; hvorved de cellelinjespecifikke celler genereres ud fra de humane embryonale stamceller.
3. Fremgangsmåde til generering af embryoidlegemer ud fra humane embryonale stamceller, hvilken fremgangsmåde omfatter, at: (a) de humane embryonale stamceller dyrkes i en suspensionskultur ifølge fremgangsmåden ifølge krav 1, hvorved der opnås ekspanderede, udifferentierede humane embryonale stamceller; og (b) de ekspanderede, udifferentierede humane embryonale stamceller underkastes dyrkningsbetingelser, der er egnet til differentiering af de humane embryonale stamceller til embryoidlegemer; hvorved embryoidlegemerne genereres ud fra de humane embryonale stamceller.
4. Fremgangsmåde til generering af cellelinjespecifikke celler ud fra embryonale stamceller, hvilken fremgangsmåde omfatter, at: (a) de humane embryonale stamceller dyrkes i en suspensionskultur ifølge fremgangsmåden ifølge krav 1, hvorved der opnås ekspanderede, udifferentierede humane embryonale stamceller; (b) de ekspanderede, udifferentierede humane embryonale stamceller underkastes dyrkningsbetingelser, der er egnet til differentiering af de ekspanderede, udifferentierede humane embryonale stamceller til embryoidlegemer; og (c) celler af embryoidlegemerne underkastes dyrkningsbetingelser, der er egnet til differentiering og/eller ekspansion af cellelinjespecifikke celler; hvorved de cellelinjespecifikke celler genereres ud fra de humane embryonale stamcell
5. Fremgangsmåde ifølge krav 1, hvorTGF3-isoformen er en TGF3-isoform 1 (TGF3i).
6. Fremgangsmåde ifølge krav 1, hvorTGF3-isoformen er en TGF3-isoform 3 (TGF33).
7. Fremgangsmåde ifølge krav 1, hvor slL6R'en forekommer i en koncentration på 15-30 ng/ml.
8. Fremgangsmåde ifølge krav 1, hvor LIF'en forekommer i en koncentration på mindst 2000 enheder pr. milliliter (u/ml).
9. Fremgangsmåde ifølge et hvilket som helst af kravene 1 -8, hvor dyrkningen udføres under xenofrie betingelser.
10. Fremgangsmåde ifølge krav 5, hvorTGFPi'en forekommer i en koncentration på mindst 0,06 ng/ml.
11. Fremgangsmåde ifølge krav 6, hvor TGFPs'en forekommer i en koncentration på eller mindst 0,5 ng/ml.
12. Fremgangsmåde ifølge et hvilket som helst af kravene 1-11, hvor bFGF'en er i en koncentration på mindst 2 ng/ml.
13. Fremgangsmåde ifølge et hvilket som helst af kravene 1-11, hvor bFGF'en er i en koncentration på mindst 4 ng/ml.
14. Fremgangsmåde ifølge krav 1, hvor IL6RIL6-kimæren er i en koncentration på mindst 25 ng/ml.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161440371P | 2011-02-07 | 2011-02-07 | |
| US201161452630P | 2011-03-14 | 2011-03-14 | |
| US201161487263P | 2011-05-17 | 2011-05-17 | |
| EP12703947.7A EP2673296B1 (en) | 2011-02-07 | 2012-02-06 | Lipoprotein complexes and manufacturing and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2767546T3 true DK2767546T3 (da) | 2019-02-04 |
Family
ID=45592833
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14150349.0T DK2767546T3 (da) | 2011-02-07 | 2012-02-06 | Lipoproteinkomplekser og fremstilling og anvendelser af disse |
| DK12703947.7T DK2673296T3 (da) | 2011-02-07 | 2012-02-06 | Lipoproteinkomplekser og fremstilling og anvendelser deraf |
| DK18195447.0T DK3466969T3 (da) | 2011-02-07 | 2012-02-06 | Lipoproteinkomplekser og fremstilling og anvendelse deraf |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK12703947.7T DK2673296T3 (da) | 2011-02-07 | 2012-02-06 | Lipoproteinkomplekser og fremstilling og anvendelser deraf |
| DK18195447.0T DK3466969T3 (da) | 2011-02-07 | 2012-02-06 | Lipoproteinkomplekser og fremstilling og anvendelse deraf |
Country Status (27)
| Country | Link |
|---|---|
| US (9) | US20120232005A1 (da) |
| EP (4) | EP2673296B1 (da) |
| JP (5) | JP6219170B2 (da) |
| KR (1) | KR20140053848A (da) |
| CN (4) | CN105288589A (da) |
| AU (3) | AU2012214672B2 (da) |
| CA (1) | CA2826158A1 (da) |
| CY (2) | CY1121317T1 (da) |
| DK (3) | DK2767546T3 (da) |
| ES (3) | ES2994009T3 (da) |
| HR (2) | HRP20190138T1 (da) |
| HU (2) | HUE042314T2 (da) |
| IL (1) | IL227634B (da) |
| IN (1) | IN2013DN07828A (da) |
| LT (2) | LT2767546T (da) |
| MX (2) | MX343907B (da) |
| PH (2) | PH12013501644A1 (da) |
| PL (2) | PL2673296T3 (da) |
| PT (2) | PT2767546T (da) |
| RS (2) | RS58243B1 (da) |
| RU (2) | RU2627173C2 (da) |
| SG (2) | SG192693A1 (da) |
| SI (2) | SI2767546T1 (da) |
| SM (2) | SMT201900045T1 (da) |
| TW (2) | TW201240671A (da) |
| WO (1) | WO2012109162A1 (da) |
| ZA (1) | ZA201305628B (da) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8206750B2 (en) | 2005-03-24 | 2012-06-26 | Cerenis Therapeutics Holding S.A. | Charged lipoprotein complexes and their uses |
| ES2617977T3 (es) | 2010-06-30 | 2017-06-20 | Csl Limited | Una formulación de lipoproteína de alta densidad reconstituida y método de producción de la misma |
| HUE042314T2 (hu) | 2011-02-07 | 2019-06-28 | Cerenis Therapeutics Holding Sa | Lipoprotein komplexek és azok gyártása és alkalmazásai |
| US9125943B2 (en) | 2012-11-02 | 2015-09-08 | Csl Limited | Reconstituted HDL formulation |
| JP2016509068A (ja) * | 2013-02-28 | 2016-03-24 | エイジェンシー・フォー・サイエンス，テクノロジー・アンド・リサーチ | クロマチン欠損細胞培養採取物からの抗体のクロマトグラフィー精製 |
| US9708354B2 (en) | 2013-03-15 | 2017-07-18 | Cerenis Therapeutics Holding Sa | Methods for the synthesis of sphingomyelins and dihydrosphingomyelins |
| EP3842443B1 (en) | 2013-03-15 | 2025-02-19 | Cerenis Therapeutics Holding SA | Methods for the synthesis of sphingomyelins and dihydrosphingomyelins |
| NZ631126A (en) | 2013-08-08 | 2018-06-29 | Csl Ltd | Contaminant removal method |
| EP2853259A1 (en) * | 2013-09-30 | 2015-04-01 | Université Pierre et Marie Curie (Paris 6) | Reconstituted high density lipoproteins composition and uses thereof |
| CA2947127A1 (en) | 2014-05-02 | 2015-11-19 | Cerenis Therapeutics Holding Sa | Hdl therapy markers |
| WO2016019333A1 (en) | 2014-07-31 | 2016-02-04 | Kinemed, Inc. | The effect of phospholipid composition of reconstituted hdl on its cholesterol efflux and anti-inflammatory properties |
| KR101671580B1 (ko) * | 2014-08-26 | 2016-11-02 | 영남대학교 산학협력단 | 미녹시딜 수용액 제조방법 |
| US10307491B2 (en) | 2015-01-30 | 2019-06-04 | The Regents Of The University Of Michigan | Liposomal particles comprising biological molecules and uses thereof |
| JP2018516847A (ja) | 2015-03-25 | 2018-06-28 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | 生体高分子薬を送達するための組成物及び方法 |
| US11642419B2 (en) * | 2015-03-25 | 2023-05-09 | The Regents Of The University Of Michigan | Compositions and methods for treating cardiovascular related disorders |
| US12257352B2 (en) | 2016-06-20 | 2025-03-25 | The Regents Of The University Of Michigan | Compositions and methods for delivery of biomacromolecule agents |
| EP3490579B1 (en) | 2016-07-27 | 2025-09-10 | Hartis-Pharma SA | Therapeutic combinations to treat red blood cell disorders |
| WO2018029505A1 (en) | 2016-08-11 | 2018-02-15 | Cerenis Therapeutics Holding Sa | Cer-001 therapy for treating familial primary hypoalphalipoproteinemia |
| AU2018210980A1 (en) * | 2017-01-23 | 2019-08-08 | Hdl Therapeutics, Inc. | Methods for treating cholesterol-related diseases |
| ES2681124B1 (es) | 2017-03-08 | 2019-06-19 | Fund Imdea Alimentacion | Usos medicos de la apolipoproteina a y de activadores de la misma |
| ES2984286T3 (es) * | 2017-08-10 | 2024-10-29 | Abionyx Pharma Sa | Apómeros |
| EP3668600B1 (en) | 2017-08-10 | 2024-05-15 | Abionyx Pharma SA | Cargomers |
| US12220462B1 (en) | 2018-02-13 | 2025-02-11 | Abionyx Pharma Sa | Complexes for delivery of cyclic dinucleotides |
| HRP20240584T1 (hr) * | 2018-07-03 | 2024-07-19 | Bristol-Myers Squibb Company | Postupak proizvodnje rekombinantnih proteina |
| JP2020138941A (ja) * | 2019-02-28 | 2020-09-03 | 国立研究開発法人理化学研究所 | バイセル及びその利用 |
| CN114746100B (zh) | 2019-11-20 | 2024-10-25 | 万能溶剂有限公司 | 用于肝再生的血浆级分 |
| US11484551B2 (en) | 2019-11-20 | 2022-11-01 | Alkahest, Inc. | Method of treating liver failure with plasma fraction IV-4 |
| JP2023509514A (ja) | 2020-01-07 | 2023-03-08 | クリールリー、 インコーポレーテッド | 医用画像分析、診断、重症度分類、意思決定、および／または疾患追跡のためのシステム、方法、およびデバイス |
| US11969280B2 (en) | 2020-01-07 | 2024-04-30 | Cleerly, Inc. | Systems, methods, and devices for medical image analysis, diagnosis, risk stratification, decision making and/or disease tracking |
| US20220392065A1 (en) | 2020-01-07 | 2022-12-08 | Cleerly, Inc. | Systems, methods, and devices for medical image analysis, diagnosis, risk stratification, decision making and/or disease tracking |
| WO2021209808A1 (en) | 2020-04-16 | 2021-10-21 | Abionyx Pharma Sa | Cer-001 therapy for treating kidney disease |
| MX2022012969A (es) | 2020-04-16 | 2022-11-09 | Abionyx Pharma Sa | Metodos para el tratamiento de condiciones agudas usando complejos basados en proteinas de union a lipidos. |
| US11752163B2 (en) | 2020-04-16 | 2023-09-12 | Abionyx Pharma Sa | CER-001 therapy for treating kidney disease |
| IL301769A (en) | 2020-10-01 | 2023-05-01 | Abionyx Pharma Sa | Methods for treating eye diseases using lipid binding protein-based complexes |
| EP4259280A4 (en) * | 2020-12-11 | 2025-02-12 | The Regents Of The University Of Michigan | Compositions and methods for preventing, attenuating, and treating medical conditions with shdl nanoparticles |
| WO2022150631A1 (en) * | 2021-01-08 | 2022-07-14 | Hdl Therapeutics, Inc | Systems and methods for reducing low attenuation plaque and/or plaque burden in patients |
| MX2023012223A (es) * | 2021-04-15 | 2023-10-26 | Abionyx Pharma Sa | Uso de complejos a base de proteinas de union a lipidos en soluciones de conservacion de organos. |
| AU2022275694A1 (en) * | 2021-05-19 | 2023-11-16 | Alkahest, Inc. | Blood plasma fractions for use in liver regeneration |
| US12406365B2 (en) | 2022-03-10 | 2025-09-02 | Cleerly, Inc. | Systems, devices, and methods for non-invasive image-based plaque analysis and risk determination |
| US20250217981A1 (en) | 2022-03-10 | 2025-07-03 | Cleerly, Inc. | Systems, methods, and devices for image-based plaque analysis and risk determination |
| US20250143657A1 (en) | 2022-03-10 | 2025-05-08 | Cleerly, Inc. | Systems, devices, and methods for non-invasive image-based plaque analysis and risk determination |
| US12440180B2 (en) | 2022-03-10 | 2025-10-14 | Cleerly, Inc. | Systems, devices, and methods for non-invasive image-based plaque analysis and risk determination |
| AU2023250345A1 (en) | 2022-04-06 | 2024-11-14 | Abionyx Pharma Sa | Methods for treating eye diseases using lipid binding protein-based complexes |
| CN119317440A (zh) | 2022-04-06 | 2025-01-14 | 阿比奥尼克斯制药公司 | 使用基于脂质结合蛋白的复合物治疗白细胞增多、内皮功能障碍和心脏炎的方法 |
| IL317448A (en) | 2022-06-10 | 2025-02-01 | Abionyx Pharma Sa | Methods for treating hyperinflammatory conditions using complexes based on lipid-binding proteins |
| JP2025519606A (ja) | 2022-06-10 | 2025-06-26 | アビオニクス ファーマ エスエー | 脂質結合タンパク質に基づく複合体を使用して急性状態を処置するための方法 |
| AU2023298303A1 (en) | 2022-06-28 | 2025-02-13 | Abionyx Pharma Sa | Compounds and processes for the synthesis of sphingomyelins |
| KR20240009061A (ko) * | 2022-07-13 | 2024-01-22 | (재)씨젠의료재단 | 혈청 내 다중 아포지단백질의 직접정량 방법 |
| IL322074A (en) | 2023-01-13 | 2025-09-01 | Abionyx Pharma Sa | Treatment using a lipid-binding protein molecule |
| WO2025093929A1 (en) | 2023-10-31 | 2025-05-08 | Abionyx Pharma Sa | Lipid binding protein molecule therapy |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4579821A (en) | 1981-11-23 | 1986-04-01 | University Patents, Inc. | Control of DNA sequence transcription |
| US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
| AU587989B2 (en) | 1984-10-16 | 1989-09-07 | Mitsubishi Chemical Corporation | DMA fragments, expression vectors, proteins, hosts, and process for production of the proteins |
| WO1986004144A1 (en) | 1984-12-31 | 1986-07-17 | International Genetic Engineering, Inc. | Peptide fragments of human apolipoprotein, type-specific antibodies and methods of use |
| GB8625435D0 (en) | 1986-10-23 | 1986-11-26 | Erba Farmitalia | Human apolipoprotein ai |
| US5128318A (en) | 1987-05-20 | 1992-07-07 | The Rogosin Institute | Reconstituted HDL particles and uses thereof |
| GB8712540D0 (en) | 1987-05-28 | 1987-07-01 | Ucb Sa | Expression of human proapolipoprotein a-i |
| US4956288A (en) | 1988-04-22 | 1990-09-11 | Biogen, Inc. | Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA |
| IT1229996B (it) | 1989-04-20 | 1991-09-20 | Cesare Sirtori | Espressione di apolipoproteina ai e apolipoproteina ai-milano in lievito e composizioni farmaceutiche che contengono dette apolipoproteine. |
| US5220043A (en) | 1991-03-21 | 1993-06-15 | Ohio University | Synthesis of D-erythro-sphingomyelins |
| WO1993000443A1 (en) | 1991-06-26 | 1993-01-07 | Bio-Technology General Corp. | Purification of recombinant apolipoprotein e from bacteria |
| US5408038A (en) | 1991-10-09 | 1995-04-18 | The Scripps Research Institute | Nonnatural apolipoprotein B-100 peptides and apolipoprotein B-100-apolipoprotein A-I fusion peptides |
| SE9103701D0 (sv) | 1991-12-13 | 1991-12-13 | Kabi Pharmacia Ab | Apolipoprotein |
| AU5457294A (en) | 1992-10-29 | 1994-05-24 | Board Of Regents, The University Of Texas System | Adenovirus-mediated ldl receptor gene transfer and targeting |
| TW402639B (en) | 1992-12-03 | 2000-08-21 | Transkaryotic Therapies Inc | Protein production and protein delivery |
| SE9203753D0 (sv) | 1992-12-11 | 1992-12-11 | Kabi Pharmacia Ab | Expression system for producing apolipoprotein ai-m |
| US5874075A (en) * | 1993-10-06 | 1999-02-23 | Amgen Inc. | Stable protein: phospholipid compositions and methods |
| US5643757A (en) | 1994-03-21 | 1997-07-01 | American Cyanamid Company | High yield production of human apolipoprotein A1 in E. coli. |
| CA2185450A1 (en) | 1994-03-22 | 1995-09-28 | Patrick Tso | Eating suppressant peptides |
| IL109558A (en) | 1994-05-04 | 2004-08-31 | Yissum Res Dev Co | DNA structures Derived from the SV40 virus that include DNA sequences External |
| US5932536A (en) | 1994-06-14 | 1999-08-03 | The Rockefeller University | Compositions for neutralization of lipopolysaccharides |
| SE9500778D0 (sv) * | 1995-03-03 | 1995-03-03 | Pharmacia Ab | Process for producing a protein |
| FR2734568B1 (fr) | 1995-05-22 | 1997-06-20 | Rhone Poulenc Rorer Sa | Nouveaux variants de l'apolipoproteine |
| US6258596B1 (en) | 1995-05-22 | 2001-07-10 | Aventis Pharmaceuticals Products Inc. | Variants of apolipoprotein A-I |
| SE9603068D0 (sv) | 1996-08-23 | 1996-08-23 | Pharmacia & Upjohn Ab | Process for purifying a protein |
| US6306433B1 (en) | 1997-08-12 | 2001-10-23 | Pharmacia Ab | Method of preparing pharmaceutical compositions |
| US6004925A (en) | 1997-09-29 | 1999-12-21 | J. L. Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6037323A (en) | 1997-09-29 | 2000-03-14 | Jean-Louis Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6046166A (en) | 1997-09-29 | 2000-04-04 | Jean-Louis Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6518412B1 (en) | 1997-09-29 | 2003-02-11 | Jean-Louis Dasseux | Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6287590B1 (en) | 1997-10-02 | 2001-09-11 | Esperion Therapeutics, Inc. | Peptide/lipid complex formation by co-lyophilization |
| GB9919713D0 (en) | 1999-08-19 | 1999-10-20 | Queen Mary & Westfield College | New medical use of high density lipoprotein |
| EP1210411B1 (en) | 1999-08-25 | 2006-10-18 | Immunex Corporation | Compositions and methods for improved cell culture |
| KR100545945B1 (ko) | 2000-07-03 | 2006-01-25 | 갈라 디자인, 인크. | 발현 벡터 |
| US20040235173A1 (en) | 2000-07-03 | 2004-11-25 | Gala Design, Inc. | Production of host cells containing multiple integrating vectors by serial transduction |
| US20030224415A1 (en) | 2001-06-29 | 2003-12-04 | Gala Design, Inc. | Selection free growth of host cells containing multiple integrating vectors |
| CA2413151C (en) | 2000-07-03 | 2012-11-27 | Gala Design, Inc. | Host cells containing multiple integrating vectors |
| AU2001271614B2 (en) | 2000-07-03 | 2007-05-31 | Catalent Pharma Solutions, Llc | Host cells containing multiple integrating vectors |
| US6664230B1 (en) | 2000-08-24 | 2003-12-16 | The Regents Of The University Of California | Orally administered peptides to ameliorate atherosclerosis |
| US7144862B2 (en) | 2000-08-24 | 2006-12-05 | The Regents Of The University Of California | Orally administered peptides to ameliorate atherosclerosis |
| US7148197B2 (en) | 2000-08-24 | 2006-12-12 | The Regents Of The University Of California | Orally administered small peptides synergize statin activity |
| US7199102B2 (en) | 2000-08-24 | 2007-04-03 | The Regents Of The University Of California | Orally administered peptides synergize statin activity |
| BR0115257A (pt) * | 2000-11-10 | 2003-08-12 | Proteopharma Aps | Análogos de apolipoproteìna |
| DK1345959T3 (da) | 2000-11-20 | 2011-09-05 | Univ Illinois | Membranscaffoldproteiner |
| IL157446A0 (en) | 2001-02-23 | 2004-03-28 | Immunex Corp Immunex Corp | Increased recovery of active proteins |
| US7217785B2 (en) | 2001-05-09 | 2007-05-15 | The Regents Of The University Of California | Cysteine-containing peptides having antioxidant properties |
| DE60226881D1 (de) | 2001-08-20 | 2008-07-10 | Zlb Bioplasma Ag | High-density -lipoprotein zur behandlung von schlaganfällen und ischämiezuständen |
| US7223726B2 (en) | 2002-01-14 | 2007-05-29 | The Regents Of The University Of California | Apolipoprotein A-I mutant proteins having cysteine substitutions and polynucleotides encoding same |
| JP2006507223A (ja) * | 2002-05-17 | 2006-03-02 | エスペリオン セラピューティクス，インコーポレイテッド | 脂質代謝異常疾患の治療方法 |
| EP1545576A2 (en) | 2002-07-30 | 2005-06-29 | Esperion Therapeutics Inc. | Methods of using non-human animal apoliprotein a-i protein |
| EP1585504A4 (en) * | 2002-11-06 | 2009-07-15 | Azaya Therapeutics Inc | Protein stabilized liposomal formulations of pharmaceutical active ingredients |
| CA2531227A1 (en) | 2003-07-03 | 2005-02-10 | Lipid Sciences Inc. | Methods and apparatus for creating particle derivatives of hdl with reduced lipid content |
| PE20050438A1 (es) * | 2003-10-20 | 2005-06-14 | Esperion Therapeutics Inc | Formulas farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y la prevencion de sindromes coronarios agudos |
| KR100560102B1 (ko) | 2004-06-25 | 2006-03-13 | 한국생명공학연구원 | 프로아포리포단백질 ａ－ⅰ 변이체와, 이를 포함하는고지혈증 또는 동맥경화증 예방 및 치료제 |
| KR101185609B1 (ko) * | 2004-07-16 | 2012-09-24 | 트러스티즈 오브 터프츠 칼리지 | 아포리포단백질 ａ１ 미메틱 및 이의 용도 |
| WO2006012632A2 (en) | 2004-07-23 | 2006-02-02 | Xencor, Inc. | Apolipoprotein a-1 derivatives with altered immunogenicity |
| US8206750B2 (en) | 2005-03-24 | 2012-06-26 | Cerenis Therapeutics Holding S.A. | Charged lipoprotein complexes and their uses |
| EP1917278A2 (en) * | 2005-08-26 | 2008-05-07 | Cerenis Therapeutics Holding SA | Compositions and methods for producing apolipoprotein gene products in lactic acid bacteria |
| US8541236B2 (en) * | 2006-12-08 | 2013-09-24 | University Of Washington | Mutant apolipoprotein A-1 polypeptide with increased resistance to oxidation and reactive carbonyls |
| US20080293102A1 (en) | 2007-02-28 | 2008-11-27 | Cerenis Therapeutics Holding, S.A. | Compositions and methods for producing apolipoprotein |
| WO2008141230A1 (en) * | 2007-05-09 | 2008-11-20 | Lawrence Livermore National Security, Llc | Methods and systems for monitoring production of a target protein in a nanolipoprotein particle |
| CA2694854C (en) | 2007-08-17 | 2016-09-27 | Csl Behring Gmbh | Methods for purification of alpha-1-antitrypsin and apolipoprotein a-i |
| US9173890B2 (en) * | 2007-09-20 | 2015-11-03 | Abbott Cardiovascular Systems Inc. | Sustained release of Apo A-I mimetic peptides and methods of treatment |
| WO2009055538A1 (en) * | 2007-10-23 | 2009-04-30 | The Cleveland Clinic Foundation | Oxidant resistant apolipoprotein a-1 and mimetic peptides |
| US20110293557A1 (en) | 2008-06-13 | 2011-12-01 | Proyecto De Biomedicina Cima, S.L. | Conjugates for the administration of biologically active compounds |
| JP5719783B2 (ja) | 2009-02-16 | 2015-05-20 | セレニス セラピューティクス ホールディング エスアー | アポリポタンパクａ−ｉ模倣物 |
| US10525152B2 (en) * | 2009-10-09 | 2020-01-07 | Signablok, Inc. | Methods and compositions for targeted imaging |
| US8987444B2 (en) | 2010-01-18 | 2015-03-24 | Msn Laboratories Private Limited | Process for the preparation of amide intermediates and their use thereof |
| HUE042314T2 (hu) | 2011-02-07 | 2019-06-28 | Cerenis Therapeutics Holding Sa | Lipoprotein komplexek és azok gyártása és alkalmazásai |
| AU2012236889A1 (en) * | 2011-03-25 | 2013-05-09 | The Trustees Of Columbia University In The City Of New York | Pegylated human HDL particle and process for production thereof |
-
2012
- 2012-02-06 HU HUE12703947A patent/HUE042314T2/hu unknown
- 2012-02-06 ES ES18195447T patent/ES2994009T3/es active Active
- 2012-02-06 CN CN201510711086.3A patent/CN105288589A/zh active Pending
- 2012-02-06 SG SG2013060512A patent/SG192693A1/en unknown
- 2012-02-06 ES ES14150349T patent/ES2716349T3/es active Active
- 2012-02-06 DK DK14150349.0T patent/DK2767546T3/da active
- 2012-02-06 US US13/367,237 patent/US20120232005A1/en not_active Abandoned
- 2012-02-06 CN CN201710493059.2A patent/CN107337728B/zh active Active
- 2012-02-06 SI SI201231508T patent/SI2767546T1/sl unknown
- 2012-02-06 DK DK12703947.7T patent/DK2673296T3/da active
- 2012-02-06 EP EP12703947.7A patent/EP2673296B1/en active Active
- 2012-02-06 EP EP14150349.0A patent/EP2767546B1/en active Active
- 2012-02-06 AU AU2012214672A patent/AU2012214672B2/en active Active
- 2012-02-06 RS RS20190073A patent/RS58243B1/sr unknown
- 2012-02-06 LT LTEP14150349.0T patent/LT2767546T/lt unknown
- 2012-02-06 HU HUE14150349A patent/HUE041797T2/hu unknown
- 2012-02-06 MX MX2013009083A patent/MX343907B/es active IP Right Grant
- 2012-02-06 RU RU2013139066A patent/RU2627173C2/ru not_active IP Right Cessation
- 2012-02-06 SM SM20190045T patent/SMT201900045T1/it unknown
- 2012-02-06 SM SM20190194T patent/SMT201900194T1/it unknown
- 2012-02-06 JP JP2013552722A patent/JP6219170B2/ja active Active
- 2012-02-06 RU RU2017126088A patent/RU2017126088A/ru not_active Application Discontinuation
- 2012-02-06 CN CN201510717344.9A patent/CN105294859A/zh active Pending
- 2012-02-06 SI SI201231514T patent/SI2673296T1/sl unknown
- 2012-02-06 CN CN201280015257.3A patent/CN103443123B/zh active Active
- 2012-02-06 DK DK18195447.0T patent/DK3466969T3/da active
- 2012-02-06 EP EP24174300.4A patent/EP4400511A3/en active Pending
- 2012-02-06 HR HRP20190138TT patent/HRP20190138T1/hr unknown
- 2012-02-06 RS RS20190093A patent/RS58275B1/sr unknown
- 2012-02-06 EP EP18195447.0A patent/EP3466969B1/en active Active
- 2012-02-06 PH PH1/2013/501644A patent/PH12013501644A1/en unknown
- 2012-02-06 PT PT14150349T patent/PT2767546T/pt unknown
- 2012-02-06 CA CA2826158A patent/CA2826158A1/en active Pending
- 2012-02-06 SG SG10201801372YA patent/SG10201801372YA/en unknown
- 2012-02-06 IN IN7828DEN2013 patent/IN2013DN07828A/en unknown
- 2012-02-06 LT LTEP12703947.7T patent/LT2673296T/lt unknown
- 2012-02-06 ES ES12703947T patent/ES2717455T3/es active Active
- 2012-02-06 WO PCT/US2012/024020 patent/WO2012109162A1/en not_active Ceased
- 2012-02-06 KR KR1020137023430A patent/KR20140053848A/ko not_active Ceased
- 2012-02-06 PT PT12703947T patent/PT2673296T/pt unknown
- 2012-02-06 PL PL12703947T patent/PL2673296T3/pl unknown
- 2012-02-06 PL PL14150349T patent/PL2767546T3/pl unknown
- 2012-02-07 TW TW101103979A patent/TW201240671A/zh unknown
- 2012-02-07 TW TW106109180A patent/TW201737935A/zh unknown
-
2013
- 2013-07-24 ZA ZA2013/05628A patent/ZA201305628B/en unknown
- 2013-07-24 IL IL227634A patent/IL227634B/en active IP Right Grant
- 2013-08-06 MX MX2016011834A patent/MX355159B/es unknown
- 2013-12-11 US US14/103,686 patent/US9187551B2/en active Active
-
2014
- 2014-07-17 US US14/334,519 patent/US10328119B2/en active Active
-
2015
- 2015-10-15 US US14/884,115 patent/US10322163B2/en active Active
- 2015-12-21 AU AU2015271986A patent/AU2015271986B2/en active Active
-
2016
- 2016-01-27 PH PH12016500191A patent/PH12016500191A1/en unknown
-
2017
- 2017-09-27 JP JP2017186171A patent/JP6720126B2/ja active Active
-
2018
- 2018-05-10 AU AU2018203258A patent/AU2018203258B9/en active Active
-
2019
- 2019-01-10 HR HRP20190072TT patent/HRP20190072T1/hr unknown
- 2019-01-17 CY CY20191100061T patent/CY1121317T1/el unknown
- 2019-01-21 CY CY20191100078T patent/CY1121318T1/el unknown
- 2019-04-29 US US16/397,944 patent/US11376309B2/en active Active
-
2020
- 2020-06-17 JP JP2020104518A patent/JP7009559B2/ja active Active
-
2022
- 2022-01-12 JP JP2022003351A patent/JP2022050603A/ja active Pending
- 2022-05-27 US US17/826,659 patent/US12364735B2/en active Active
-
2023
- 2023-08-04 US US18/365,367 patent/US11969456B2/en active Active
- 2023-08-04 US US18/365,328 patent/US11998587B2/en active Active
-
2024
- 2024-09-03 JP JP2024151092A patent/JP2024170492A/ja active Pending
-
2025
- 2025-06-11 US US19/235,337 patent/US20250302916A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12060575B2 (en) | Methods of expanding embryonic stem cells in a suspension culture | |
| DK2767546T3 (da) | Lipoproteinkomplekser og fremstilling og anvendelser af disse | |
| US12391918B2 (en) | Media for culturing stem cells | |
| EP3633025B1 (en) | Culture media, cell cultures and methods of culturing pluripotent stem cells in an undifferentiated state | |
| AU2015203310B2 (en) | Media for Culturing Stem Cells | |
| AU2012261726B2 (en) | Media for Culturing Stem Cells | |
| HK1259231B (en) | Media for culturing stem cells | |
| HK40026788B (en) | Culture media, cell cultures and methods of culturing pluripotent stem cells in an undifferentiated state |